Predict your next investment

Venture Capital
greybirdventures.com

See what CB Insights has to offer

Investments

12

About GreyBird Ventures

GreyBird Ventures is an early stage venture capital firm that invests in companies with technology for precision medicine diagnosis.

GreyBird Ventures Headquarter Location

31 Pond View Lane

Concord, Massachusetts, 1742,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest GreyBird Ventures News

Genetika+ Raises $10M for Personalized Medicine for Psychiatry Solution

Sep 30, 2021

What You Should Know:  – Genetika+ , a female-founded startup focused on developing personalized medicine for psychiatry conditions, that the company has closed a $10 million Series A round led by GreyBird Ventures with participation from Meron Capital, Jumpspeed Ventures , Sapir Venture Partners, Howard Morgan Chairman of B Capital Group and Michael Zeisser of FMZ Ventures and former Chairman, Investments at Alibaba Group. – Founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., Genetika is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company’s Brain-in-a-Dish technology helps physicians find the best treatment for their patients. Personalizing Depression Treatment Depression affects daily functioning and quality of life for more than 300 million people worldwide, making it a leading cause of disability globally. Beyond the human cost, in the United States alone, the economic impact of the depression was more than $326 billion annually in 2018. During the COVID-19 pandemic, depression rates have risen threefold, with the largest increase in young adults. While a large number of antidepressants are available, there is currently no objective way for physicians to choose among these drugs based on a patient’s specific brain biology. Initially prescribed treatments are only successful about one-third of the time. Genetika+’s lead solution personalized antidepressant treatment for each patient. The company’s novel Brain-in-a-Dish technology allows for a first-of-its-kind in vitro screen, in which a simple blood draw is used to predict the best antidepressant or combination therapy for that patient. This approach eliminates months or years of trial-and-error prescribing for depression patients, often accompanied by debilitating side effects. This solution for depression is just the beginning for Genetika+, which will apply its platform to develop personalized solutions for conditions across the psychiatric and neurological space. Expansion Plans The funding will accelerate the company’s next phase, including expanded clinical trials, increased manufacturing capabilities, and the establishment of a clinical lab in Boston, Massachusetts. The company is accelerating growth through increased hiring for multiple positions over the next 12 months in Boston and Israel to support research and business development activities across the U.S. market.

GreyBird Ventures Investments

12 Investments

GreyBird Ventures has made 12 investments. Their latest investment was in Genetika+ as part of their Series A on September 9, 2021.

CBI Logo

GreyBird Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/30/2021

Series A

Genetika+

$10M

Yes

1

9/20/2021

Series A

Platomics

$16.42M

Yes

3

6/8/2021

Series A

Angstrom Bio

$3M

Yes

4

12/2/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

8/5/2019

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/30/2021

9/20/2021

6/8/2021

12/2/2020

8/5/2019

Round

Series A

Series A

Series A

Series A

Series C

Company

Genetika+

Platomics

Angstrom Bio

Subscribe to see more

Subscribe to see more

Amount

$10M

$16.42M

$3M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

3

4

10

10

GreyBird Ventures Team

3 Team Members

GreyBird Ventures has 3 team members, including current Founder, Managing Partner, Tom Miller.

Name

Work History

Title

Status

Scott Gazelle

Founder

Current

Tom Miller

Siemens Healthineers, Analogic, Zeiss, Siemens, and Massachusetts General Hospital

Founder, Managing Partner

Current

Michael W. Devlin

Managing Partner

Current

Name

Scott Gazelle

Tom Miller

Michael W. Devlin

Work History

Siemens Healthineers, Analogic, Zeiss, Siemens, and Massachusetts General Hospital

Title

Founder

Founder, Managing Partner

Managing Partner

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.